CD274 and non-small cell lung carcinoma: This phase III randomized trial showed a median PFS of 0.3 months (95% CI, 6.7 to NR) for immunotherapy versus 6.0 months (95% CI, 4.2‐6.2) for chemotherapy,, with a hazard ratio (HR) for disease progression or death of 0.50 (95% CI, 0.37‐0.68); P < .001).4 Median OS was 30.0 months (95% CI, 18.3‐NR) in the pembrolizumab arm versus 14.2 months (95% CI, 9.8‐19.0) in the chemotherapy group with an HR of 0.63 (95% CI, 0.47‐0.86; P = .002).15 Another randomized trial KEYNOTE‐042 investigated pembrolizumab in the NSCLC first‐line treatment with PD‐L1 score ≥1%.